All other individuals completed at least 21 times of follow-up following dose two or more to time 50. Non-adjuvanted SCB-2019 (S-Trimer protein alone), was well tolerated with regards to solicited regional undesirable occasions generally, with only 1 report of minor pain following the initial dose (3 g) and non-e following the second dose (figure 2). […]